

**1. PATIENT INFORMATION**
**\*\*PLEASE FAX COPY OF: PRESCRIPTION CARD FRONT & BACK and CLINICAL NOTES/LABS\*\***

|         |  |                          |             |            |      |                                |                               |
|---------|--|--------------------------|-------------|------------|------|--------------------------------|-------------------------------|
| NAME:   |  | ADDRESS:                 |             | CITY:      |      | STATE:                         | ZIP:                          |
| DOB:    | SEX: <input type="checkbox"/> F <input type="checkbox"/> M | PHONE:                   | CELL PHONE: |            | SSN: |                                |                               |
| HEIGHT: | WEIGHT:  | HIPAA CONTACT/CAREGIVER: |             | ALLERGIES: |      | <input type="checkbox"/> LATEX | <input type="checkbox"/> NKDA |

**2. CLINICAL INFORMATION**

 DATE OF DIAGNOSIS: \_\_\_\_\_ HISTORY:  NEW  RESTART  CONTINUING | TB TEST: NEGATIVE DATE \_\_\_\_\_ HBV NEGATIVE OR TREATED:  YES  NO

|  |                     |  |   |                                      |                                       |   |                                     |                                       |                                  |                                  |   |                                |                                       |
|--|---------------------|--|---|--------------------------------------|---------------------------------------|---|-------------------------------------|---------------------------------------|----------------------------------|----------------------------------|---|--------------------------------|---------------------------------------|
| <b>DIAGNOSIS / ICD-10:</b> <input type="checkbox"/> ATOPIC DERMATITIS (L20.9) <input type="checkbox"/> PSORIATIC ARTHRITIS (L40.5) <input type="checkbox"/> PSORIASIS VULGARIS (L40.0) <input type="checkbox"/> PSORIASIS UNSPECIFIED (L40.9) <input type="checkbox"/> HIDRADENITIS SUPPURATIVA (L73.2) <input type="checkbox"/> OTHER _____ |                     |  |   |                                      |                                       |   |                                     |                                       |                                  |                                  |   |                                |                                       |
| BSA % _____  | HURLEY STAGE: _____ | <input type="checkbox"/> HANDS   | <input type="checkbox"/> NAILS              | <input type="checkbox"/> PALMS       | <input type="checkbox"/> ARMS         | <input type="checkbox"/> FEET           | <input type="checkbox"/> SOLES      | <input type="checkbox"/> LEGS         | <input type="checkbox"/> SCALP   | <input type="checkbox"/> FACE    | <input type="checkbox"/> GROIN/GENITALS | <input type="checkbox"/> TORSO | <input type="checkbox"/> OTHER: _____ |
| <b>FAILED TREATMENTS:</b>  |                     | <b>** ENTER LENGTH OF TREATMENT AND DATES BELOW/BESIDE FAILED THERAPY **</b> |   |                                      |                                       |   |                                     | <b>CURRENT THERAPY:</b>               |                                  |                                  |   |                                |                                       |
| <b>BIOLOGICS</b>   |                     | <input type="checkbox"/> CIMZIA  | <input type="checkbox"/> COSENTYX           | <input type="checkbox"/> ENBREL      | <input type="checkbox"/> HUMIRA       | <input type="checkbox"/> ORENCIA        | <input type="checkbox"/> REMICADE   | <input type="checkbox"/> RITUXAN      | <input type="checkbox"/> SIMPONI | <input type="checkbox"/> STELARA | <input type="checkbox"/> TALTZ          |                                |                                       |
| <b>TOPICALS</b>  |                     | <input type="checkbox"/> BETAMETHASONE                                       | <input type="checkbox"/> CALCIPOTRIENE      | <input type="checkbox"/> CLOBETASOL  | <input type="checkbox"/> FLUOCINONIDE | <input type="checkbox"/> SALICYLIC ACID | <input type="checkbox"/> TAZAROTENE | <input type="checkbox"/> OTHERS _____ |                                  |                                  |   |                                |                                       |
| <b>ORAL MEDICATIONS</b>  |                     | <input type="checkbox"/> METHOTREXATE _____                                  | <input type="checkbox"/> CYCLOSPORINE _____ | <input type="checkbox"/> OTHER _____ |                                       |   |                                     | <input type="checkbox"/> UVA          | <input type="checkbox"/> UVB     |                                  |   |                                |                                       |
| <b>NOTES:</b>  |                     |  |   |                                      |                                       |   |                                     |                                       |                                  |                                  |   |                                |                                       |

**3. Rx**

 IF SHIPPING TO PRESCRIBER: NEXT APPT DATE: \_\_\_\_\_  FIRST FILL  ALL FILLS | PATIENT RECEIVED STARTER DOSE:  YES: DATE \_\_\_\_\_  NO

| MEDICATION                           | DOSE/STRENGTH   | DIRECTIONS  | QUANTITY                        | REFILLS           |
|--------------------------------------|---|---|---------------------------------|-------------------|
| <input type="checkbox"/> COSENTYX®   | <input type="radio"/> 150mg/ml PFS<br><input type="radio"/> 150mg/ml Sensoready Pen<br>Dose: <input type="radio"/> 150mg <input type="radio"/> 300mg  | <input type="radio"/> <b>Loading Dose:</b> Inject Sub-Q weeks 0, 1, 2, and 3<br><input type="radio"/> Inject Sub-Q on day 29<br><input type="radio"/> <b>Maintenance Dose:</b> Inject Sub-Q every 4 weeks   | 4-Week Supply                   | 1                 |
| <input type="checkbox"/> DUPIXENT®   | <input type="radio"/> 300mg/2 mL PFS w/ shield  | <input type="radio"/> <b>Loading Dose:</b> Inject 600mg Sub-Q on Day 1<br><input type="radio"/> <b>Maintenance Dose:</b> Inject 300mg Sub-Q every other week  | 2<br>4-Week Supply              | None              |
| <input type="checkbox"/> ENBREL®     | <input type="radio"/> 25mg/0.5ml PFS<br><input type="radio"/> 25mg Vial<br><input type="radio"/> 50mg/ml Mini Cartridge<br><input type="radio"/> 50mg/ml PFS<br><input type="radio"/> 50mg/ml Sureclick | <input type="radio"/> <b>Adult Loading Dose:</b> 50mg Sub-Q twice a week (3-4 days apart) for 3 months<br><input type="radio"/> <b>Adult Maintenance Dose:</b> Inject 50mg Sub-Q once a week<br><input type="radio"/> <b>Pediatric Dose &gt; 138lb(63kg)</b> Inject 50mg Sub-Q once a week<br><input type="radio"/> <b>Pediatric Dose &lt; 138lb(63kg)</b> Inject 0.8mg/kg (____mg) Sub-Q once a week | 8<br>4-Week Supply              | 2                 |
| <input type="checkbox"/> HUMIRA®     | <input type="radio"/> Psoriasis Starter Kit<br><input type="radio"/> 40mg Pen<br><input type="radio"/> 40mg PFS   | <input type="radio"/> <b>Loading Dose:</b> Inject 80mg Sub-Q on Day 1, 40mg on Day 8, and every other week<br><input type="radio"/> Inject 40mg Sub-Q <b>EVERY OTHER</b> week   | 1 Starter Pack<br>4-Week Supply | None              |
|                                      | <input type="radio"/> HS Starter Kit<br><input type="radio"/> 40mg Pen<br><input type="radio"/> 40mg PFS  | <input type="radio"/> <b>Loading Dose:</b> 160mg Sub-Q on day 1 OR 80mg Sub-Q days 1 & 2, then inject 80mg Sub-Q on day 15<br><input type="radio"/> <b>Maintenance Dose:</b> Inject 40mg SQ weekly  | 1 Starter Pack<br>4-Week Supply | None              |
| <input type="checkbox"/> ORENCIA®    | <input type="radio"/> 125mg/ml ClickJect<br><input type="radio"/> 125mg/ml PFS  | <input type="radio"/> Inject 125mg Sub-Q once a week  | 4-Week Supply                   |                   |
| <input type="checkbox"/> OTEZLA®     | <input type="radio"/> Starter Pack<br><input type="radio"/> 30mg Tablets  | <input type="radio"/> <b>Loading Dose:</b> Take 1 tablet on day 1, then twice daily as directed.<br><input type="radio"/> <b>Maintenance Dose:</b> Take 1 tablet by mouth twice daily.  | 1 Starter Pack<br>60            | None              |
| <input type="checkbox"/> SIMPONI®    | <input type="radio"/> 50mg/0.5ml SmartJect<br><input type="radio"/> 50mg/0.5ml PFS  | <input type="radio"/> Inject 50mg Sub-Q once a month  | 4-Week Supply                   |                   |
| <input type="checkbox"/> STELARA®    | <input type="radio"/> 45mg PFS (<100kg/220lbs)<br><input type="radio"/> 45mg/ml Vial<br>WT: _____<br><input type="radio"/> 90mg PFS (>100kg/220lbs)   | <input type="radio"/> <b>Loading Dose: &lt;60kg(132lbs)</b> Inject 0.75mg/kg (____mg) Sub-Q on day 1 and day 29.<br><input type="radio"/> <b>Loading Dose:</b> Inject 1 PFS Sub-Q on day 1 and day 29.<br><input type="radio"/> <b>Maintenance:</b> Inject the contents of 1 PFS Sub-Q every 12 weeks   | 1                               | 1                 |
| <input type="checkbox"/> TALTZ®      | <input type="radio"/> 80mg/mL Autoinjector<br><input type="radio"/> 80mg/mL PFS   | <input type="radio"/> <b>Loading Dose:</b> Inject 160mg Sub-Q once, followed by 80mg at week 2, then<br><input type="radio"/> Inject 80mg Sub-Q weeks 4,6,8, and 10, then<br><input type="radio"/> Inject 80mg Sub-Q at week 12.  | 3<br>2<br>1                     | None<br>1<br>None |
|                                      |   | <input type="radio"/> <b>Loading Dose: (Psoriatic Arthritis):</b> Inject 160 mg Sub-Q on day 1<br><input type="radio"/> <b>Maintenance Dose:</b> Inject 80mg Sub-Q every 4 weeks  | 2<br>1                          | None<br>None      |
| <input type="checkbox"/> TREMFYA®    | <input type="radio"/> 100mg/ml PFS  | <input type="radio"/> <b>Loading Dose:</b> Inject 100mg Sub-Q on week 1 and on day 29<br><input type="radio"/> <b>Maintenance Dose:</b> Inject 100mg Sub-Q every 8 weeks  | 1<br>1                          | 1                 |
| <input type="checkbox"/> XELJANZ®    | <input type="radio"/> 5mg Tablet  | <input type="radio"/> Take one tablet by mouth twice daily  | 60                              |                   |
| <input type="checkbox"/> XELJANZ XR® | <input type="radio"/> 11mg Tablet   | <input type="radio"/> Take one tablet by mouth once daily   | 30                              |                   |
| <input type="checkbox"/>             |   |   |                                 |                   |

**4. PRESCRIBER INFORMATION**
**UPON PA DENIAL:**  SEND FORMULARY ALTERNATIVES  DRAFT APPEAL

|  |          |                     |        |                  |
|--|----------|---------------------|--------|------------------|
| <b>PRESCRIBER SIGNATURE:</b>   |          |                     |        |                  |
| <small>I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment. By signing this form and utilizing our services, you are authorizing Broadway Pharmacy and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies and Co-Pay Assistance/Foundation.</small> |          |                     |        |                  |
| Signature: _____   |          | Date: _____         |        | Signature: _____ |
| Substitution Permitted   |          | Dispense As Written |        |                  |
| PRESCRIBER NAME:   | ADDRESS: | CITY:               | STATE: | ZIP:             |
| OFFICE CONTACT:  | PHONE:   | FAX:                | NPI:   | DEA:             |